PBCAR269B / Precision BioSci - LARVOL DELTA

Precision BioSciences Reports First Quarter and 2021 Financial Results and Provides Business Update (Businesswire) - “PBCAR0191…Precision will continue to monitor the results for durability from this eLD regimen and expects to report updated interim results in June at ASCO 2021. PBCAR20A…Precision expects to provide an interim update for the PBCAR20A study in 2021. PBCAR269A…Precision expects to provide an interim update in 2021. Precision also expects to initiate the combination arm of its ongoing Phase 1/2a clinical study with PBCAR269A and nirogacestat, SpringWorks Therapeutics’ investigational gamma secretase inhibitor, in the first half of 2021. PBCAR269B…Precision is conducting IND-enabling studies for PBCAR269B and expects to file an IND application in early 2022."

IND • New P1/2 trial • P1/2 data • Preclinical • Acute Lymphocytic Leukemia • Chronic Lymphocytic Leukemia • Hematological Malignancies • Leukemia • Lymphoma • Multiple Myeloma • Non-Hodgkin’s Lymphoma • Oncology • Small Lymphocytic Lymphoma • Solid Tumor